Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL: Pirfenidone in HPS-ILD
NCT04193592Phase 2Unknown
- Start
- Dec 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of pirfenidone in Hermansky-Pudlak syndrome (HPS), interstitial lung disease (ILD). Status: unknown.
02
Drugs
pirfenidone
03
Conditions
Hermansky-Pudlak syndrome (HPS)interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT04193592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04193592.